Jump to main content
Jump to site search

Issue 42, 2018
Previous Article Next Article

Graphene quantum dots against human IAPP aggregation and toxicity in vivo

Author affiliations

Abstract

The development of biocompatible nanomaterials has become a new frontier in the detection, treatment and prevention of human amyloid diseases. Here we demonstrated the use of graphene quantum dots (GQDs) as a potent inhibitor against the in vivo aggregation and toxicity of human islet amyloid polypeptide (IAPP), a hallmark of type 2 diabetes. GQDs initiated contact with IAPP through electrostatic and hydrophobic interactions as well as hydrogen bonding, which subsequently drove the peptide fibrillization off-pathway to eliminate the toxic intermediates. Such interactions, probed in vitro by a thioflavin T kinetic assay, fluorescence quenching, circular dichroism spectroscopy, a cell viability assay and in silico by discrete molecular dynamics simulations, translated to a significant recovery of embryonic zebrafish from the damage elicited by IAPP in vivo, as indicated by improved hatching as well as alleviated reactive oxygen species production, abnormality and mortality of the organism. This study points to the potential of using zero-dimensional nanomaterials for in vivo mitigation of a range of amyloidosis.

Graphical abstract: Graphene quantum dots against human IAPP aggregation and toxicity in vivo

Back to tab navigation

Supplementary files

Publication details

The article was received on 04 Sep 2018, accepted on 17 Oct 2018 and first published on 18 Oct 2018


Article type: Paper
DOI: 10.1039/C8NR07180B
Citation: Nanoscale, 2018,10, 19995-20006
  •   Request permissions

    Graphene quantum dots against human IAPP aggregation and toxicity in vivo

    M. Wang, Y. Sun, X. Cao, G. Peng, I. Javed, A. Kakinen, T. P. Davis, S. Lin, J. Liu, F. Ding and P. C. Ke, Nanoscale, 2018, 10, 19995
    DOI: 10.1039/C8NR07180B

Search articles by author

Spotlight

Advertisements